Price comparison only·Not medical advice·Using this site means you accept our Terms & Privacy·Always confirm with your pharmacist·Price comparison only·Not medical advice·Using this site means you accept our Terms & Privacy·Always confirm with your pharmacist·
Pharmacy Benefit Management Services Agreement with Integrated Prescription Management
Pharmacy benefit manager: Integrated Prescription Management, Inc. Term begins August 30, 2022; the end date is not stated in the posted document. Effective August 30, 2022 with a one year initial term that renews automatically. Exhibit A, Fees, is posted in full with the brand and generic AWP discounts and dispensing fees. The agreement covers the county's indigent health population.
No page of the posted agreement is redacted. Exhibit A (fees) is posted in full.
The rubric
Clause by clause
Each item quotes the contract and cites the page it came from. Items whose pages are redacted are marked unclear and left out of the score.
Fiduciary duty and loyalty
Weight 7 of 100, model section Section 2.4
Not addressed
Three of five models read this as missing; Claude Opus 5 and Kimi K3 called it bad because Section 3.8 on page 4 makes IPM an independent contractor and not an agent of the county. We re-read pages 2 to 4 and the relationship clause in Section 16 on page 9. Nothing imposes a duty of loyalty or care on IPM, requires disclosure of conflicts, or provides for disgorgement, and the independent contractor language describes the legal relationship rather than authorizing self dealing. Under the majority rule the item is not addressed rather than contradicted, and the minority reading is recorded here.
No verbatim quote is available for this clause.
Model contract says
The PBM owes duties of loyalty and care solely to the plan and its members, must disclose all direct and indirect compensation and every economic conflict, and must disgorge anything retained in breach without the plan proving damages.
Without a loyalty duty the PBM is free to put its own affiliates and revenue ahead of the plan when it exercises discretion over formularies, networks and pricing.
Model votes: Kimi K3 bad, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 bad, Gemini 3.1 Pro missing
Full disclosure of compensation and conflicts
Weight 6 of 100, model section Sections 2.4, 2.6
Not addressed
All five models reached this verdict. The only compensation terms are the fees in Exhibit A on page 11 and the billing article on pages 4 and 5. Nothing requires IPM to disclose affiliate ownership, related entity revenue or payments to consultants or brokers, and no officer certifies anything on any schedule. Section 3.7 on pages 3 and 4 puts a disclosure duty on the county toward its members, not on IPM toward the county.
No verbatim quote is available for this clause.
Model contract says
All PBM and related-entity compensation, affiliate ownership touching plan claims, and payments to consultants or brokers are disclosed, and a named officer certifies quarterly and annually that everything has been disclosed and remitted.
Hidden revenue streams are the main way plans overpay. Officer certification puts a name on the line.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Ownership and affiliate disclosure exhibit
Weight 3 of 100, model section Proposed Exhibit A-5
Not addressed
Four of five models read this as missing; GPT 5.6 Sol called it partial because page 12 requires a Texas Form 1295 certificate of interested parties at award, renewal or amendment. We re-read page 12. The Form 1295 clause is a state procurement requirement aimed at the bidder's interested parties, not a signed exhibit listing owners, subsidiaries, affiliated pharmacies, purchasing organizations or rebate aggregators, and it carries no duty to refresh within 30 days of a change in control. Exhibit A is a fee sheet and Exhibit B is a HIPAA business associate agreement, so no ownership exhibit exists.
No verbatim quote is available for this clause.
Model contract says
A signed exhibit lists every owner, parent, subsidiary, affiliate, group purchasing organization, rebate aggregator, mail order pharmacy and specialty pharmacy tied to the PBM, and the PBM must refresh it within 30 days of any change in ownership or control.
The model contract has no ownership exhibit, and the Nautilus Health Institute review of version 3.5 scored conflict of interest 70 of 100 for that gap. A plan cannot police affiliate pricing, steering or GPO pass through if it does not know which companies are affiliates.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol partial, Claude Opus 5 missing, Gemini 3.1 Pro missing
Definitions that close loopholes
Weight 5 of 100, model section Section 1
Contradicts the model
Four of five models read this as bad; Grok 4.6 called it partial because a definitions article does exist. The definitions on pages 1 and 2 let IPM pick the pricing benchmark in its sole discretion, decide what counts as a brand name drug, and determine generic status using a combination of data fields it never discloses. Rebate, manufacturer revenue, affiliate, specialty and MAC are not defined at all. Because the terms that drive price are set by the vendor rather than by economic function, the definitions do the opposite of what the model contract by Mark Cuban and collaborators requires.
"Average Wholesale Price" or "A WP" will mean the benchmark price established by Medi Span, or another nationally reporting service of pharmaceutical prices as selected by IPM , in its sole discretion
Page 1Model contract says
Rebate, manufacturer revenue, affiliate, specialty, generic and pharmacy are defined by economic function, not by label, so value cannot be relabeled (for example as fees) to escape pass-through or guarantees.
Most PBM revenue leakage happens inside definitions. A narrow definition of rebate lets fees, grants and administrative payments stay with the PBM.
Model votes: Kimi K3 bad, Grok 4.6 partial, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad
100% pass-through of manufacturer revenue
Weight 11 of 100, model section Section 4
Not addressed
All five models reached this verdict. The word rebate appears twice, in Section 3.7 on page 4 where the county must disclose rebates to members and in Section 24 on page 10 where taxes on rebate amounts are the county's cost. Neither clause promises the county any share of manufacturer revenue, sets a remittance schedule or lists excludable claims. On this text the county has no contractual claim to any rebate at all.
No verbatim quote is available for this clause.
Model contract says
One hundred percent of manufacturer revenue of every kind is paid to the plan, quarterly within 30 days of quarter end, with only a closed list of excludable claims.
Rebates and other manufacturer payments are the largest dollar item in most PBM contracts. Anything less than 100% of everything is money left with the PBM.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Affiliate pharmacy pricing at acquisition cost
Weight 5 of 100, model section Section 3.2
Not addressed
All five models reached this verdict. The recitals on page 1 mention a network of retail and mail order pharmacies, but Exhibit A on page 11 prices only retail claims at discounts off average wholesale price plus dispensing fees. Nothing prices claims from IPM owned or related pharmacies at acquisition cost, and there is no documentation default if acquisition records are not produced.
No verbatim quote is available for this clause.
Model contract says
Claims dispensed by PBM-owned or economically related pharmacies (mail, specialty, retail) are invoiced at net acquisition cost plus a stated dispensing fee, with no retained margin and a documentation default if records are not produced.
Owned pharmacies are where PBMs earn the most margin. Pricing them at cost removes the incentive to steer patients into the PBM's own channels.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Benchmark ceiling and cheapest lawful option
Weight 3 of 100, model section Section 3.3
Not addressed
Four of five models read this as missing; Claude Opus 5 called it partial because the generic line in Exhibit A on page 11 lists usual and customary charge as one pricing alternative. We re-read page 11. The generic formula names average wholesale price less a discount, usual and customary or generic MAC without saying which applies or that the lowest controls, brand claims have no ceiling at all, and no clause tests any claim against a published cash benchmark in any channel. That is not a benchmark ceiling, so the majority reading stands.
No verbatim quote is available for this clause.
Model contract says
Plan claim cost can never exceed a published benchmark, for example the transparent cash price at a benchmark site, in any channel and for any drug, and the ceiling is checked claim by claim rather than on average.
A ceiling protects the plan from paying more through the contract than the public can pay in cash, and a claim level test stops a favorable average from hiding individual overcharges.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 partial, Gemini 3.1 Pro missing
Cash price protection and deductible credit
Weight 3 of 100, model section Section 3.4
Not addressed
All five models reached this verdict. Section 5.7 on page 5 stops IPM and network pharmacies from billing members beyond copayments and deductibles, which is a real protection but a different one. Nothing says a member never pays more than the pharmacy cash price, nothing credits cash purchases toward a deductible, and nothing addresses accumulator adjustments.
No verbatim quote is available for this clause.
Model contract says
A member never pays more than the pharmacy cash price or the cheapest lawful price, every cash purchase counts toward the deductible and out of pocket maximum, and no accumulator adjustment is applied against member assistance unless the sponsor elects it in writing.
Members routinely pay more through the plan than the cash price on the shelf, and a cash purchase that does not count toward the deductible punishes the member for finding the cheaper price.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
MAC list governance
Weight 5 of 100, model section Section 3.5
Weaker than the model
Three of five models read this as partial; Claude Opus 5 called it bad because the MAC list is never tied to what pharmacies are paid, and Gemini 3.1 Pro called it missing because no governance clause exists. The phrase Generic MAC appears only in the Exhibit A fee line on page 11, so a MAC list does affect what the county pays. The agreement never defines the list, never discloses it, never puts it on an update schedule, never says one list governs both county billing and pharmacy payment, and gives pharmacies no appeals path. The subject is touched by the pricing exhibit but none of the governance the model contract requires is present, which is the partial verdict.
Generic: A WP less 80%, U&C or Generic MAC plus $2.50 di spensing fee;
Page 11Model contract says
A single MAC list applies to both what the plan pays and what pharmacies are paid, it is disclosed, updated on a schedule, and pharmacies have an appeals path with defined timelines.
Two MAC lists (one for the plan, one for pharmacies) is the classic spread pricing mechanism.
Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 bad, Gemini 3.1 Pro missing
No spread pricing
Weight 9 of 100, model section Sections 2.5, 3.1, 3.5
Contradicts the model
Three of five models read this as bad; Gemini 3.1 Pro and Kimi K3 called it missing because no clause speaks to spread in words. We re-read pages 4, 5 and 11. The county is billed at the average wholesale price formulas in Exhibit A, while Section 5.8 confirms that pharmacy payment terms live in IPM's separate agreements with network pharmacies, and Section 5.2 says the money the county sends is not an asset of the plan. Nothing requires the county to pay what the pharmacy is paid plus a disclosed fee, so the structure permits IPM to keep the difference in every channel. The majority reading stands, with reduced confidence because the permission comes from structure rather than an express retention clause.
Client understands that IPM ' s agreements w ith Network Pharmacies may allow etwork Pharmacies to review payments made by IPM related to the Covered Pharmacy Services.
Page 5Model contract says
The plan pays exactly what the pharmacy is paid plus a disclosed administrative fee. The PBM retains no difference between the two, in any channel.
Spread pricing is an undisclosed markup on every claim. Eliminating it is the single clearest test of a transparent contract.
Model votes: Kimi K3 missing, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing
GPO and purchasing entity pass-through
Weight 4 of 100, model section Section 5
Not addressed
All five models reached this verdict. No group purchasing organization, volume credit, purchase discount or supplier payment appears in the definitions on pages 1 and 2, the compensation article on pages 4 and 5, Exhibit A on page 11 or anywhere else in the 17 pages.
No verbatim quote is available for this clause.
Model contract says
Purchase discounts, volume credits and supplier payments received by the PBM or any related purchasing entity (including offshore GPOs) flow to the plan, allocated on disclosed drivers.
PBMs moved much of their manufacturer revenue into affiliated GPOs after rebate scrutiny increased. A contract that only covers rebates misses this.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Plan sponsor controls the formulary
Weight 4 of 100, model section Section 6
Weaker than the model
Three of five models read this as partial; Gemini 3.1 Pro and Kimi K3 called it missing because the word formulary never appears. We re-read pages 3 and 4. Section 3.8 gives the county sole authority to control and administer its plans, and Sections 3.1 and 3.2 make the county supply the benefit design and approve changes to it, which is a real if general form of control. There is no formulary approval right, no lowest net cost analysis and no utilization management reporting by drug, and Section 2.1 on page 2 lets IPM change the Services on its own. The majority reading of partial stands because the county controls plan design even though it does not control the drug list.
Client acknowledges that it has the so le authority to control and admi ni ster its Plans.
Page 4Model contract says
The plan sponsor approves the formulary and every change, receives lowest-net-cost analysis, and gets utilization management outcomes by drug each quarter.
A PBM-controlled formulary can favor high-list-price, high-rebate drugs that cost the plan more overall.
Model votes: Kimi K3 missing, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing
Lowest net cost standard and book of business comparison
Weight 3 of 100, model section Section 6
Not addressed
All five models reached this verdict. The benefit design clauses on pages 3 and 4, the reporting clause in Section 2.7 on page 3 and Exhibit A on page 11 contain no lowest net cost standard, no annual comparison against IPM's book of business and no duty to explain when a drug is placed above a cheaper equivalent.
No verbatim quote is available for this clause.
Model contract says
Formulary decisions must meet a lowest net cost standard for this plan, the PBM delivers an annual comparison against its whole book of business, and any drug placed above a cheaper equivalent is disclosed with the reason.
Rebate driven formularies can favor a high list price drug that returns more rebate but costs the plan more after the rebate. A stated standard and a book of business comparison make that trade visible.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Pharmacy network protections and anti-steering
Weight 7 of 100, model section Section 7
Contradicts the model
Four of five models read this as bad; Gemini 3.1 Pro called it missing because no protective clause exists to be weaker than the model. Section 2.3 on page 2 puts network composition entirely in IPM's discretion with no promise about which or how many pharmacies participate, so there is no any willing pharmacy right and no anti steering rule. Section 5.8 on page 5 then makes the county remit money whenever a pharmacy later claims an underpayment, which is the opposite of claims being final when adjudicated. The text permits the harms the model clause exists to prevent.
Additions or deletions to the Network shall be in IP M ' s sole discretion and !PM makes no warranty that any specific pharmacy or number of pharmacies will be in the Network at any time.
Page 2Model contract says
Claims are final when adjudicated (no retroactive clawbacks), reimbursement is not conditioned on volume, the PBM may not steer claims into its own pharmacies, and any willing pharmacy may participate at the plan's terms.
Steering and clawbacks push independent pharmacies out and route patients to PBM-owned channels, reducing choice and often raising cost.
Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro missing
Most favored pricing and market check
Weight 3 of 100, model section Section 8
Not addressed
All five models reached this verdict. Pricing lives in Exhibit A on page 11 and in Section 5.3 on page 4, which lets IPM change fees after the first year. Nothing promises the county pricing as good as any comparable client and nothing creates a market check with a meet, credit or release remedy.
No verbatim quote is available for this clause.
Model contract says
The plan automatically receives pricing at least as good as any comparable client, and can run an annual market check with a meet, credit or release remedy.
Multi-year contracts drift out of market. Without a market check the plan is locked into stale pricing.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Audit rights, data access and reporting
Weight 6 of 100, model section Section 9
Weaker than the model
Four of five models read this as partial; Gemini 3.1 Pro called it missing because the only audit clause sits in the HIPAA exhibit. We re-read pages 3, 5 and 16. The audit right in Exhibit B, section 7 on page 16 lets either party audit compliance with the business associate agreement and inspect records of protected health information, not claims pricing or vendor revenue. The main agreement gives the county only IPM's standard reports as amended from time to time under Section 2.7 on page 3, deems reports accurate if not disputed within 45 days under Section 3.6, and requires payment in full while an invoice is disputed under Section 5.5 on page 5. An audit right exists but it does not reach the money, which is partial.
Either Party, or its representative, shall be entitled after ten (10) business days' prior written notice to the other Party, to audit that Party to verify their compliance with the terms of th is Agreement.
Page 16Model contract says
The plan may audit with its own auditor, receives full claims-level and financial data on a schedule without asking, has pre-adjudication claims access, and no data is withheld as proprietary.
You cannot enforce what you cannot see. Audit and data rights are how every other clause gets verified.
Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro missing
Plan sponsor owns all plan data
Weight 4 of 100, model section Sections 9.4, 9.5
Contradicts the model
All five models reached this verdict. Section 7.1 on page 6 lets IPM use, reproduce or adapt member information in any manner it deems appropriate, including product research and development, and Section 6.5 on the same page makes IPM's databases, adjudication logic and report formats IPM's copyrighted property. Section 7.2 lets IPM use de identified information as it sees fit. The county is never named owner of its claims, eligibility or rebate data, nothing requires machine readable delivery on request, and nothing bars reuse or resale. This is the reverse of the model contract's data ownership clause.
IPM may use, reproduce, or adapt Covered Person information in any manner it deems appropriate, including product research and development
Page 6Model contract says
The plan sponsor is the sole owner of claims, eligibility, accumulator, rebate and every derived data set, the PBM delivers it in machine readable form on request, and the PBM may not reuse, license or sell it.
Data ownership decides who can switch vendors, run an audit or check a guarantee. A PBM that owns or licenses plan data can charge for it, withhold it at termination, or resell it.
Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad
Performance guarantees with real remedies
Weight 2 of 100, model section Section 10
Not addressed
All five models reached this verdict. No performance guarantee, quarterly measurement on plan specific data, cash reconciliation or dollar for dollar shortfall payment appears in the services article on pages 2 and 3, Exhibit A on page 11 or the liability and termination sections on pages 4 and 7.
No verbatim quote is available for this clause.
Model contract says
Guarantees are measured quarterly on plan-specific data, reconciled in cash, and shortfalls are paid dollar for dollar rather than as capped credits.
Guarantees that are capped or measured on book-of-business data rarely pay out.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Self executing enforcement and two strikes exit
Weight 3 of 100, model section Sections 10, 12.5
Not addressed
Three of five models read this as missing; Claude Opus 5 called it bad because Section 9.6 on page 7 caps IPM's liability at six months of administrative fees, and GPT 5.6 Sol called it partial because Section 4 on page 4 allows termination for an uncured material breach. We re-read pages 4 and 7. There are no liquidated damages, no automatic credits, no report deadlines and no two strikes exit, so nothing self executing exists. The liability cap and the 30 day cure right are real weaknesses, and they are recorded in the termination and audit findings, but they do not address the subject of automatic remedies. Under the majority rule the item is not addressed.
No verbatim quote is available for this clause.
Model contract says
Missed guarantees and late reports trigger liquidated damages or automatic credits without the plan having to prove damages, and a second material breach or regulatory integrity failure lets the sponsor terminate without penalty.
A right the plan has to litigate to enforce is rarely enforced. Automatic remedies and a defined exit after a repeat failure change the PBM incentives without a lawsuit.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol partial, Claude Opus 5 bad, Gemini 3.1 Pro missing
Amendments only in writing
Weight 2 of 100, model section Section 11
Contradicts the model
Three of five models read this as bad; Grok 4.6 and Kimi K3 called it partial because Section 18 on page 9 requires mutual signed consent for amendments. We re-read pages 4 and 9. Section 18 opens with the words except as otherwise set forth herein, and Section 5.3 on page 4 is exactly such an exception: after the first year IPM may change the fees or other pricing on its own, with only documentation delivered before the county budget cycle. Section 2.1 on page 2 also lets IPM change the Services from time to time, and Exhibit B on page 17 adopts HIPAA driven changes without a signed amendment. The economic terms can move without the county's signature, which is the harm the model clause exists to prevent.
After the initial term of the Agreement, !PM may change the Fees or other pricing under th is Agreement.
Page 4Model contract says
No amendment is effective unless signed by both parties; the PBM cannot change economic terms by notice, portal update or updated exhibit.
Unilateral amendment rights let a PBM quietly rewrite pricing mid-term.
Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad
Termination without penalty
Weight 2 of 100, model section Section 12
Weaker than the model
All five models reached this verdict. Section 4 on page 4 lets the county end the agreement on 90 days notice with no stated termination fee, and the fiscal funding clause in Section 27 on page 12 adds a budget based exit each fiscal year. The catch is that a notice termination takes effect only at the end of the then current one year term, and the agreement renews automatically, so a late decision means another year, while the exclusivity clause on page 8 blocks the county from lining up another vendor meanwhile. There is no regulatory integrity trigger. Useful but weaker than the model's clean exit.
Either party may terminate this Agreement upon ninety (90) days prior written notice to the other party, which shall become effective only at the end of the then expiri ng term or extension thereof.
Page 4Model contract says
The plan may terminate for convenience with reasonable notice and without penalty, earned amounts are never forfeited, and a regulatory integrity event is grounds for termination.
Termination penalties and forfeited rebates are how plans get trapped in bad contracts.
Model votes: Kimi K3 partial, Grok 4.6 partial, GPT 5.6 Sol partial, Claude Opus 5 partial, Gemini 3.1 Pro partial
Specialty drug pricing controls
Weight 3 of 100, model section Sections 1.16, 3.2(d)
Not addressed
All five models reached this verdict. Exhibit A on page 11 lists only retail pharmacy fees and the recitals on page 1 mention mail order pharmacies. Specialty is never defined, no drug level specialty rate exists, and nothing prices affiliate specialty claims at acquisition cost anywhere in the 17 pages.
No verbatim quote is available for this clause.
Model contract says
Specialty is defined by function, drug-level rates act as a ceiling in every channel, and specialty claims at affiliate pharmacies are priced at acquisition cost.
Specialty drugs are a minority of claims but the majority of spend, and most are dispensed by PBM-owned specialty pharmacies.
Model votes: Kimi K3 missing, Grok 4.6 missing, GPT 5.6 Sol missing, Claude Opus 5 missing, Gemini 3.1 Pro missing
Gag clause (red flag)
Weight 0 of 100, model section Sections 9, 14
Contradicts the model
All five models reached this verdict. Section 6.1 on page 5 defines confidential information to include pricing information and the agreement itself with all exhibits, which sweeps in the Exhibit A fee schedule. Section 6.2 bars either party from revealing that information without the other's written consent, which may be withheld for any reason, and the only stated exception in Section 6.3 is a subpoena with notice so the other party can object. There is no carve out for the Texas Public Information Act, the county's auditors or advisors, elected officials or the public, and Section 6.6 on page 6 backs the clause with injunctive relief. This is the red flag the item tracks.
" Confidential Information" includes, but is not limited to, proprietary business and technical information, patient and third-party payor lists, statistical data, computer programs, pricing information, the Agreement and all exhibits, addenda and alterations hereto
Page 5Model contract says
Nothing in the contract stops the plan from sharing pricing, rebate or performance data with its own advisors, auditors, members, the public or lawmakers, and nothing stops pharmacies from telling patients about cheaper options.
Confidentiality clauses that treat pricing terms as trade secrets are what keep taxpayers from seeing what their government pays. This is why the A&M contract is partly blacked out.
Model votes: Kimi K3 bad, Grok 4.6 bad, GPT 5.6 Sol bad, Claude Opus 5 bad, Gemini 3.1 Pro bad
The council
Five models, every verdict published
The full independent review from each model, the agreement grid, and the synthesis that reconciles them.
Five models from five providers read the full extracted text independently, without seeing one another, and scored every rubric item. Unanimous verdicts stand. Where the council split, the reconciled verdict and the reasoning behind it are written out in the clause by clause section above, and the split is marked here so nobody has to take the resolution on faith. Items a model could not read because of redaction are unclear and excluded from the score. The council agreed outright on 12 of 23 clauses.
Swipe the grid sideways to see every seat and the published verdict.
Clause by clause verdicts by each council model and the published consensus
Clause
Claude Opus 5
Gemini 3.1 Pro
GPT 5.6 Sol
Grok 4.6
Kimi K3
Published
Fiduciary duty and loyaltySplit
Contradicts the model
Not addressed
Not addressed
Not addressed
Contradicts the model
Not addressed
Full disclosure of compensation and conflicts
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Ownership and affiliate disclosure exhibitSplit
Not addressed
Not addressed
Weaker than the model
Not addressed
Not addressed
Not addressed
Definitions that close loopholesSplit
Contradicts the model
Contradicts the model
Contradicts the model
Weaker than the model
Contradicts the model
Contradicts the model
100% pass-through of manufacturer revenue
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Affiliate pharmacy pricing at acquisition cost
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Benchmark ceiling and cheapest lawful optionSplit
Weaker than the model
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Cash price protection and deductible credit
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
MAC list governanceSplit
Contradicts the model
Not addressed
Weaker than the model
Weaker than the model
Weaker than the model
Weaker than the model
No spread pricingSplit
Contradicts the model
Not addressed
Contradicts the model
Contradicts the model
Not addressed
Contradicts the model
GPO and purchasing entity pass-through
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Plan sponsor controls the formularySplit
Weaker than the model
Not addressed
Weaker than the model
Weaker than the model
Not addressed
Weaker than the model
Lowest net cost standard and book of business comparison
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Pharmacy network protections and anti-steeringSplit
Contradicts the model
Not addressed
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Most favored pricing and market check
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Audit rights, data access and reportingSplit
Weaker than the model
Not addressed
Weaker than the model
Weaker than the model
Weaker than the model
Weaker than the model
Plan sponsor owns all plan data
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Performance guarantees with real remedies
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Self executing enforcement and two strikes exitSplit
Contradicts the model
Not addressed
Weaker than the model
Not addressed
Not addressed
Not addressed
Amendments only in writingSplit
Contradicts the model
Contradicts the model
Contradicts the model
Weaker than the model
Weaker than the model
Contradicts the model
Termination without penalty
Weaker than the model
Weaker than the model
Weaker than the model
Weaker than the model
Weaker than the model
Weaker than the model
Specialty drug pricing controls
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Not addressed
Gag clause (red flag)
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Contradicts the model
Council synthesis: where the five models agreed and where they split
How the council worked
Five frontier models read the same 17 page text of the agreement between Grayson County, Texas and Integrated Prescription Management, Inc. (IPM), dated August 30, 2022, including Exhibit A (fees) and Exhibit B (the business associate agreement). The models were Claude Opus 5 (Anthropic), GPT 5.6 Sol (OpenAI), Gemini 3.1 Pro (Google), Grok 4.6 (xAI) and Kimi K3 (Moonshot AI). Each read independently against the same 23 item rubric, which we derived from the open source model PBM contract published by Mark Cuban and collaborators. We then reconciled the reads under a fixed rule: a verdict held by three or more seats stands; with no majority the middle vote is taken after re-reading the cited pages; unclear is reserved for redacted text, and nothing here is redacted. Every seat's vote on every item is published on this page.
Where the five models agreed
Nothing on manufacturer money. All five found no rebate pass through, no disclosure of PBM compensation, no group purchasing pass through, no lowest net cost standard, no most favored pricing and no performance guarantees. The word rebate appears only in a member disclosure duty (page 4) and a tax clause (page 10).
Nothing on affiliate or specialty pricing. Exhibit A (page 11) prices only retail claims, and no clause prices IPM owned pharmacies at acquisition cost or defines specialty.
Data runs the wrong way. Section 7.1 (page 6) lets IPM use member information in any manner it deems appropriate, including product research, and Section 6.5 makes IPM's databases and report formats its property.
A gag clause. Section 6.1 (page 5) makes pricing information and the agreement with all exhibits confidential, Section 6.2 requires consent to reveal it, and the only exception is a subpoena.
Termination is partial. Either party may exit on 90 days notice with no fee stated (page 4), but only at the end of the then current term, and the deal renews automatically.
Where they split, and how it was resolved
Fiduciary duty. Claude Opus 5 and Kimi K3 voted bad on Section 3.8 (page 4), which makes IPM an independent contractor and not an agent of the county; three voted missing. Majority missing: the clause does not authorize self dealing.
Ownership exhibit. GPT 5.6 Sol voted partial on the Form 1295 certificate of interested parties clause (page 12); four voted missing. Majority missing. Form 1295 is a state procurement filing, not an affiliate exhibit with a refresh duty.
Definitions. Four bad, Grok 4.6 partial. Majority bad: IPM picks the pricing benchmark in its sole discretion and decides what is brand and what is generic (page 1).
Benchmark ceiling. Claude Opus 5 partial because the generic fee line lists usual and customary as one alternative (page 11); four missing. Majority missing, since nothing says the lowest alternative controls and brand claims have no ceiling.
MAC governance. Three partial, Claude Opus 5 bad, Gemini 3.1 Pro missing. Majority partial: Generic MAC appears only in the fee line (page 11), a list without governance.
Spread pricing. Claude Opus 5, GPT 5.6 Sol and Grok 4.6 bad; Gemini 3.1 Pro and Kimi K3 missing. Majority bad. On re-read, the county is billed on average wholesale price formulas while Section 5.8 (page 5) confirms pharmacies are paid under IPM's separate agreements, so retained spread is permitted by structure.
Formulary control. Three partial, two missing. Majority partial: Section 3.8 gives the county sole authority over its plans, but the word formulary never appears.
Network protections. Four bad, Gemini 3.1 Pro missing. Majority bad on Section 2.3 (page 2), which puts network additions and deletions in IPM's sole discretion.
Audit. Four partial, Gemini 3.1 Pro missing. Majority partial: the only audit right is in the business associate agreement (page 16) and reaches privacy compliance, not money.
Enforcement. Claude Opus 5 bad on the liability cap (page 7), GPT 5.6 Sol partial on the cure and terminate clause (page 4), three missing. Majority missing.
Amendments. Three bad, two partial. Majority bad: Section 18 (page 9) requires signed amendments except as otherwise set forth, and Section 5.3 (page 4) lets IPM change pricing alone after the first year.
What only one model caught
GPT 5.6 Sol alone noticed that the Form 1295 clause (page 12) is the only place the contract touches ownership disclosure. It was outvoted, but the observation is correct.
Claude Opus 5 alone flagged that Section 19.2 (page 10) terminates the agreement automatically if the parties cannot agree a pricing adjustment within 60 days of a change in law or industry practice.
Grok 4.6 alone noted that Section 5.2 (page 4) says the money the county pays IPM is not an asset of the plan, which makes offsets and retained spread easier.
The bottom line
The reconciled score is 8.5 out of 100, a Red flag, on 100 points of scored weight with 0 points unclear, and the gag clause flag is set. The five seats landed between 1.0 (Gemini 3.1 Pro) and 12.0 (Grok 4.6), with GPT 5.6 Sol at 11.5 and Claude Opus 5 and Kimi K3 at 7.5; every seat reached the Red flag band. The disagreement was only about whether silence should be labelled missing or bad.
The same contract written up for different readers: the people who negotiate these agreements and the people who pay for them.
Good news, bad news: the short version
Good news
The whole document is public. All 17 pages, including the Exhibit A fee schedule (page 11), are posted and readable, so nothing had to be excluded from the score.
The county keeps control of its plan. Section 3.8 (page 4) says the county has the sole authority to control and administer its plans, and Sections 3.1 and 3.2 (page 3) put the benefit design in the county's hands.
Members cannot be balance billed. Section 5.7 (page 5) bars IPM and network pharmacies from collecting anything from covered persons beyond copayments and deductibles, and the clause survives termination.
No termination fee. Section 4 (page 4) lets either party end the agreement on 90 days written notice with no penalty stated, and the fiscal funding clause in Section 27 (page 12) ties every renewal to the commissioners court approving a budget.
Most ancillary services are free. Exhibit A (page 11) prices ID cards, claim forms, prior authorizations, standard reporting and four other services at $0.00 each.
Amendments are supposed to be signed. Section 18 (page 9) requires mutual written consent for changes, as a default rule.
Bad news
No rebates come back. Nothing in the agreement gives the county any manufacturer revenue, and the only mentions of rebates (pages 4 and 10) concern member disclosure and taxes.
Spread is allowed. The county pays average wholesale price formulas under Exhibit A (page 11) while pharmacies are paid under IPM's separate agreements (Section 5.8, page 5), and nothing requires the two amounts to match.
IPM can raise prices alone. Section 5.3 (page 4) lets IPM change the fees or other pricing after the initial term by delivering documentation before the budget cycle, which hollows out the signed amendment rule.
The vendor picks the pharmacies. Section 2.3 (page 2) makes network additions and deletions IPM's sole discretion with no any willing pharmacy right, and Section 5.8 (page 5) makes the county pay whenever a pharmacy later claims an underpayment.
The vendor owns the data and may reuse it. Section 7.1 (page 6) lets IPM use member information in any manner it deems appropriate, including product research, and Section 6.5 makes the databases and report formats IPM's property.
The county cannot audit the money. The only audit right is in the business associate agreement (page 16) and covers privacy compliance; reports are deemed accurate if not disputed within 45 days (page 3) and disputed invoices must be paid in full (page 5).
Pricing is confidential. Section 6.1 (page 5) treats pricing information and the agreement with all exhibits as confidential, with no Texas Public Information Act carve out.
Remedies are capped. Section 9.6 (page 7) limits IPM's total liability to the administrative fee paid over the previous six months.
Exclusivity plus auto renewal. Section 10 (page 8) makes IPM the county's exclusive PBM, and the term renews yearly unless notice lands before the term ends (page 4).
The number
The reconciled score is 8.5 out of 100, a Red flag, on 100 points of scored weight with nothing unclear, and the gag clause flag is set. Four items earned half credit (MAC governance, formulary control, audit rights and termination) and everything else scored zero, either because the text contradicts the model contract by Mark Cuban and collaborators or because it says nothing. What would move the number most is a full pass through of manufacturer revenue, worth 11 points, followed by a plain statement that the county pays exactly what the pharmacy is paid plus a disclosed fee, worth 9. Removing pricing from the confidentiality clause would not change the score but would clear the red flag.
Check our work
Read a page
Pull the text of any page we extracted and compare it with the original.
We already have this document and the posted copy includes its pricing attachments, so you do not need to request the contract. What a request can still add is the incorporated proposal, the claims and rebate reports the plan receives, and any later amendments. Generate a Texas Public Information Act letter for Grayson County that names those pieces, send it in your own name, and log what comes back.
The model contract we score against is the open source PBM contract published by Mark Cuban and collaborators, version 3.5. BetterBuy Rx did not write it and is not affiliated with its authors. Read the original on LinkedIn.